German chemical giant BASF has introduced NeoHelix Regenerate and SkinNexus Collag3n, positioning both as breakthrough tools for skin rejuvenation and long-term structural preservation.

 

NeoHelix Regenerate is described as a precision peptide designed to work with the skin’s own repair systems, targeting damaged collagen and triggering adaptive renewal. 

 

The technology draws inspiration from collagen-hybridizing peptide (CHP) concepts developed by U.S. start-up 3Helix, marking a cross-industry push into advanced bio-inspired cosmetics.

 

SkinNexus Collag3n, meanwhile, focuses on “collagen banking,” delivering a bio-identical Collagen III fragment produced via yeast fermentation. It was developed in collaboration with Bota Biosciences and is designed to replicate human collagen sequences while supporting extracellular matrix function.

 

“Both ingredients are impressive examples of the innovative power that strong partnerships can unleash. By working with the skin’s own biology, we are moving from traditional collagen-support claims to more advanced renewal and preservation across multiple levels,” said Lucilene Veira Nunes, Business Management BASF Beauty Care Solutions.

 

Collagen—responsible for skin strength and structure—declines naturally with age, and BASF is betting that biotech-driven actives can help reverse visible signs of deterioration.

 

NeoHelix Regenerate is engineered to locate damaged areas of skin and enhance localized repair activity. In clinical testing on women aged 60–70, researchers reported a 41% reduction in damaged collagen after 56 days, alongside a 65% increase in hyaluronic acid levels.

 

Additional in vivo studies showed visible improvements in skin thickness, firmness, and forehead wrinkles, with the peptide outperforming a benchmark ingredient across all measured outcomes.

 

The innovation stems from BASF’s partnership with 3Helix, leveraging single-stranded collagen-like peptides designed for high bioactivity and targeted skin interaction.

 

SkinNexus Collag3n takes a different approach, aiming to strengthen the skin’s overall collagen network rather than targeting isolated damage.

 

In 3D dermis models, it supported a 48% increase in Collagen I, 82% in Collagen III, and 71% in Collagen V, indicating broad-spectrum support for skin structure.

 

Clinical trials on women aged 53–70 showed improved firmness, reduced sagging, and visible wrinkle reduction after just four weeks—outperforming a collagen benchmark used at ten times the concentration.

 

The ingredient is produced through advanced biomanufacturing powered by Bota Biosciences and designed for scalable, cost-efficient production.

 

Its development also draws on computational optimization via the SAION AI Platform, which automates experimental design and accelerates biological discovery.